Page 14 - P4403.14-V104 May OTC Magazine 2025 NI PRINT 10.04.25_Neat

14 ALLERGY

FAST AND EFFECTIVE POWERFUL

ALLERGY RELIEF HAYFEVER RELIEF

Save
15% Off

Trade

tablet syrup tablet

6+ years 1+ years 12+ years
Symptomatic control of all Relief of symptoms associated
allergic conditions responsive with seasonal allergic rhinitis:
to antihistamines including:
• Sneezing, a runny nose, stuffy
• Hayfever and other allergies nose, itchy nose, itchy and
e.g., pet, house dust mite, watery eyes, sore and
and mould spore allergies scratchy throat
• Food allergies such as itchy • Hayfever relief non-drowsy
skin, skin rash, and hives in most people
• Also relieves the itchy rash
of chickenpox

chlorphenamine maleate fexofenadine hydrochloride

Pirilieve Hayfever Relief 120mg Film-Coated Tablets
(fexofenadine hydrochloride). Indications: Relief of symptoms
associated with seasonal allergic rhinitis. Legal category: GSL.
Licence Holder: Chanelle Medical Unlimited Company,
Fast allergy Dublin Road, Loughrea, Co. Galway, Ireland.
30 only Information about Pirilieve, including adverse reactions,
relief that acts in Pharmacy
precautions, contraindications and method of use
can be found at:
mins

Piriton Children’s Allergy Syrup and Piriton Allergy Tablets (chlorphenamine maleate). Indications: Symptomatic relief of
allergic conditions including hayfever. Symptomatic relief of itch associated with chickenpox. Legal category: P. Licence Holder:
Haleon UK Trading Limited, The Heights, Weybridge, Surrey, KT13 0NY, UK. Information about this product, including adverse
reactions, precautions, contraindications and method of use can be found at: http://www.medicines.org.uk/emc/medicine/16103,
https://www.medicines.org.uk/emc/product/3928/smpc
Trade marks are owned by or licensed to the Haleon group of companies. PM-GB-PIRI-25-00026

18/03/2025 15:50
SM6809 2025_Piri DPS PLOF Numark Wholesaler 2025 2 PRESS_READY.indd All Pages 18/03/2025 15:50
SM6809 2025_Piri DPS PLOF Numark Wholesaler 2025 2 PRESS_READY.indd All Pages
P4403.14-V104 May OTC Magazine 2025 NI.indd 14
11/04/2025 09:24:20
P4403.14-V104 May OTC Magazine 2025 NI.indd 14 11/04/2025 09:24:20